Faran Shimi Pharmaceutical Company
Faran Shimi Pharmaceutical Company was established in 2001 with the nature of a production cooperative on a land with an area of about 17,000 square meters in Tuysarkan Industrial Town.
This company started its work with the production of salicylic acid and joined Golrang Industrial Group in 2016.
Growth, employment and progress
After the formation of Golrang Pharmaceutical Investment Company in 2009, Faran Chemi Pharmaceutical Company was introduced as one of the member companies of this holding and due to its background and having basic infrastructure, it quickly attracted the attention of the holding's managers. Faran Chemi pharmaceutical company rapidly developed its growth and potentials by taking advantage of four main parameters of managerial, financial, scientific and executive arms. Currently, the factory with this complex has created a suitable employment environment for Tuysarkan city, most of which are local graduates, including bachelor's, master's, and doctorate pharmacists. "Currently, this complex has more than There are 350 personnel directly, which will have the capacity to recruit up to 500 people with the launch of new lines.
In the LVHV sector, using the skills and knowledge of expert professors in the holding, under the format of Hasti Aria Chemical Company, this company is able to produce very sensitive drugs with high technology.
In the field of finished medicine production, in addition to the hemodialysis solution production line, since February 2019, Faran has started to build a production line of all kinds of solids (pills) with a capacity of one hundred and fifty million tablets per year, which, with the efforts of the workers, has benefited The vector has arrived. As the first product, two mg sublingual buprenorphine tablets were produced, whose primary ingredient, buprenorphine hydrochloride, is also produced by the same company's API department.
For example, it has been able to produce the raw material buprenorphine hydrochloride. Buprenorphine tablets are used as a substitute for methadone tablets, and in addition to being more effective, they have many advantages over methadone, including non-addictiveness.
Currently, all the domestic companies authorized to produce buprenorphine use the product produced in Faran Chemical Pharmaceutical Company, and due to its high quality, the possibility of exporting to other countries is also available. Also, the company started to build a production line for opium products.
This line is completely in accordance with international standards and has obtained all necessary permits such as GMP certificate from the Ministry of Health. Other forms of buprenorphine tablets as well as oxycodone, naloxone, acetaminophen-oxycodone, fentanyl and methadone are also in the production plan and will gradually be released to the pharmaceutical market.
vision
Placing in the first rank of pharmaceutical companies in the field of narcotic drugs production in Iran and being among the top 10 active pharmaceutical companies in the field of narcotics in the world until 1401
Mission
Production of all kinds of effective medicinal substances in the field of narcotics, from the stage of opium extraction to substances The effectiveness of all synthetics and also the production of ready-to-use drugs in solid forms The highest quality to meet domestic and foreign needs with a competitive price
This company started its work with the production of salicylic acid and joined Golrang Industrial Group in 2016.
CEO of Faran Shimi Pharmaceutical
Aliakbar Molaei
CEO
In the pharmaceutical industry, challenges are inevitable, but our journey towards excellence is defined by how we overcome them. Through teamwork, resilience, and unwavering commitment, we tackle obstacles head-on, turning adversity into opportunity and emerging stronger and more resilient by leveraging our collective strengths and diverse perspectives. At the heart of our company's growth and expansion lies a steadfast dedication to continuous improvement, innovation, and investing in our people, creating a fertile ground for transformation and progress as we navigate the challenges of the pharmaceutical industry. Our commitment to driving positive change, delivering impactful solutions, and making a lasting difference in the lives of patients worldwide fuels our unwavering determination towards a brighter, healthier future for all.
